ANTIBODY-DRUG CONJUGATES AND THEIR USES FOR CANCER THERAPY

CY1125910T1Undetermined Publication Date: 2026-04-17INATHERYS

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CY20231100035T
Authority / Receiving Office: CY · CY
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2018-04-10
Filing Date: 2023-01-23
Publication Date: 2026-04-17
Estimated Expiration: 2043-01-23

Application Information

Patent Timeline

10 Apr 2018

Priority

23 Jan 2023

Application

CY20231100035T

17 Apr 2026

Publication

CY1125910T1

IPC: A61K47/65; A61K47/68; A61P35/00; A61P35/02

CPC: A61K47/65; A61K47/6851; A61K47/6889; A61K47/68031; C07K16/2881; A61K47/26; C07K2317/92; A61K47/6803

Inventors: LAUNAY Pierre; SOUCHET Hervé

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Technology Topics

Disease Antiendomysial antibodies

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to TfR, the transferrin receptor, and wherein the drug is preferably selected from a cytotoxic drug. Such antibody-drug conjugates are particularly useful in the treatment of proliferative diseases including cancers, such as lymphoma or leukemia.

Need to check novelty before this filing date? Find Prior Art